Skip to main content

Actinium Pharmaceuticals, Inc.

ATNM
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001388320

No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.

Holders of 5% or more of ATNM

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Actinium Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Actinium Pharmaceuticals, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Actinium Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ATNM
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 29, 202512:10 PM ETVanguard Group Inc13G/A4.39%1.37M shares–Below 5%Jun 30, 2025SEC
Jul 16, 20257:02 PM ETBlackRock, Inc.13G/A1.50%463.0K shares–Below 5%Jun 30, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Actinium Pharmaceuticals, Inc. shares.

No Form 144 notices for Actinium Pharmaceuticals, Inc. are on file.